Skip to content
by Legal Desire
4 December 2020

Latham Advises the Underwriters in Silverback Therapeutics’ Initial Public Offering

Advising firms

Deal team

14 lawyers named
LawyerFirmSeniorityPracticeOffice
Brian Cuneo Lead Latham & Watkins LLP Partner life sciences capital markets Bay Area
Phillip Stoup Latham & Watkins LLP Associate life sciences capital markets Bay Area
Raul Gonzalez Latham & Watkins LLP Associate life sciences capital markets Bay Area
Taimi Jacobson Latham & Watkins LLP Associate life sciences capital markets Bay Area
Christopher Hazuka Latham & Watkins LLP Partner intellectual property Bay Area
Robert Yeh Latham & Watkins LLP Associate intellectual property San Diego
Elizabeth Richards Latham & Watkins LLP Partner regulatory Washington, D.C.
Betty Pang Latham & Watkins LLP Counsel regulatory Bay Area
Barrett Tenbarge Latham & Watkins LLP Associate regulatory Washington, D.C.
Alyssa Lattner Latham & Watkins LLP Associate regulatory Washington, D.C.
Julie Shin Latham & Watkins LLP Associate regulatory Washington, D.C.
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Amy Feinberg Latham & Watkins LLP Associate tax Washington, D.C.
James Metz Latham & Watkins LLP Partner benefits and compensation Bay Area

Stated terms

Stated value
USD 242m (US$241.5 million)
What the figure measures
Issue size
Client
Not stated
Counterparties
Silverback Therapeutics, Inc. (Issuer)